[Advances in the research of BRAF(V600E) gene mutation correlated with papillary thyroid carcinoma].
The increase in the incidence of papillary thyroid carcinoma (PTC) is a serious threat to public health. V-raf murine sarcoma viral oncogene homolog B(BRAF)(V600E) gene mutation is not only the common genetics factors, but also is the early event in process of thyroid carcinogenesis. We mainly illustrate the mechanism of BRAF(V600E) gene in genesis and development of PTC and the correlation of BRAF(V600E) gene mutation and the clinicopathological characteristics of PTC. Finally, we briefly summarize some scientific achievements about tyrosine kinase inhibitors targeted for BRAF(V600E) gene and their clinical prospect in terms of translation medicine concept. In summary, BRAF(V600E) gene is expected to be a new molecular marker of PTC, which will take a new hope for individualized precise treatment for patients with PTC.
Department of Etiology, Shanxi Provincial Tumor Institute, Taiyuan 030013, China.
X Q
XQ
Xu
Department of Head and Neck Surgery, Shanxi Provincial Tumor Hospital, Taiyuan 030013, China.
X H
XH
Wang
Department of Etiology, Shanxi Provincial Tumor Institute, Taiyuan 030013, China.
J X
JX
Jing
D000818:Animals; D002277:Carcinoma / Q000235:genetics*; D002291:Carcinoma, Papillary / Q000235:genetics*; D006801:Humans; D051379:Mice; D009154:Mutation; D012106:Research; D013964:Thyroid Neoplasms / Q000235:genetics*